Found: 21
Select item for more details and to access through your institution.
Second cancers in Hodgkin's lymphoma long-term survivals: A 60-year single institutional experience with real-life cohort of 871 patients.
- Published in:
- 2018
- By:
- Publication type:
- journal article
PERIPHERAL T-CELL LYMPHOMA, UNSPECIFIED - THE ANALYSIS OF THE DATA FROM THE CZECH LYMPHOMA STUDY GROUP (CLSG) REGISTRY.
- Published in:
- Biomedical Papers of the Medical Faculty of Palacky University in Olomouc, 2007, v. 151, n. 1, p. 103, doi. 10.5507/bp.2007.019
- By:
- Publication type:
- Article
Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Everolimus Plus Exemestane in Postmenopausal Patients with HR<sup>+</sup> Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis.
- Published in:
- Advances in Therapy, 2013, v. 30, n. 10, p. 870, doi. 10.1007/s12325-013-0060-1
- By:
- Publication type:
- Article
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2022, v. 195, n. 1, p. 55, doi. 10.1007/s10549-022-06662-9
- By:
- Publication type:
- Article
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 168, n. 1, p. 127, doi. 10.1007/s10549-017-4518-8
- By:
- Publication type:
- Article
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study.
- Published in:
- Oncology, 2012, v. 82, n. 4, p. 218, doi. 10.1159/000336892
- By:
- Publication type:
- Article
Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 7, p. N.PAG, doi. 10.3390/diagnostics12071740
- By:
- Publication type:
- Article
Zhodnocení účinnosti neoadjuvantní chemoterapie s platinovým derivátem u pacientek se zárodečnou mutací v genech BRCA1 a BRCA2 - retrospektivní analýza souboru pacientek s karcinomem prsu léčených v MOÚ Brno
- Published in:
- Journal of the Czech & Slovak Societies for Oncology / Klinická Onkologie, 2019, v. 32, p. 31
- By:
- Publication type:
- Article
Doporučení pro sledování žen se vzácnějšími genetickými příčinami nádorů prsu a ovarií.
- Published in:
- Journal of the Czech & Slovak Societies for Oncology / Klinická Onkologie, 2019, v. 32, p. 6
- By:
- Publication type:
- Article
Editorial.
- Published in:
- Journal of the Czech & Slovak Societies for Oncology / Klinická Onkologie, 2016, v. 29, n. S3, p. 3S3
- By:
- Publication type:
- Article
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 10, p. 1908, doi. 10.1002/cncr.28010
- By:
- Publication type:
- Article
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1598, doi. 10.3390/cancers14071598
- By:
- Publication type:
- Article
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
- Published in:
- Cancers, 2021, v. 13, n. 7, p. 1586, doi. 10.3390/cancers13071586
- By:
- Publication type:
- Article
Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer.
- Published in:
- In Vivo, 2020, v. 34, n. 6, p. 3441, doi. 10.21873/invivo.12183
- By:
- Publication type:
- Article
Aktuální léčebné vyhlídky onkologických pacientů jsou slibné.
- Published in:
- Remedia, 2023, v. 33, n. 3, p. 176
- By:
- Publication type:
- Article
Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
- Published in:
- Oncology Reports, 2014, v. 32, n. 4, p. 1695, doi. 10.3892/or.2014.3346
- By:
- Publication type:
- Article
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Kardiovaskulární komplikace nádorů a jejich léčby.
- Published in:
- Internal Medicine / Vnitrni Lekarstvi, 2017, v. 63, n. 3, p. 200
- By:
- Publication type:
- Article
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor‐positive breast cancer: The pre‐operative “Arimidex” compared to Tamoxifen (PROACT) trial.
- Published in:
- Cancer (0008543X), 2006, v. 106, n. 10, p. 2095, doi. 10.1002/cncr.21872
- By:
- Publication type:
- Article